In our July issue, Sven Kili focuses his regular analysis of current clinical trends on the far-reaching and in some cases devastating impact of the Covid-19 pandemic. From new investment trends and delayed trials to changes to approval processes, the shockwaves of the pandemic have been felt in almost every corner of the cell and gene therapy field.
